



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/596,958	06/20/2000	Jihyun Francis Kim	19603/3286(CRF D-2062B)	5427

7590 05/07/2003

Michael L Goldman Esq
Nixon Peabody LLP
Clinton Square P O Box 31051
Rochester, NY 14603

EXAMINER

KUBELIK, ANNE R

ART UNIT	PAPER NUMBER
1638	15

DATE MAILED: 05/07/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action	Application No.	Applicant(s)
	09/596,958	KIM ET AL.
	Examiner Anne R. Kubelik	Art Unit 1638

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 22 April 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

PERIOD FOR REPLY [check either a) or b)]

- a) The period for reply expires ____ months from the mailing date of the final rejection.
- b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.
ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

1. A Notice of Appeal was filed on 20 December 2002. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. The proposed amendment(s) will not be entered because:
 - (a) they raise new issues that would require further consideration and/or search (see NOTE below);
 - (b) they raise the issue of new matter (see Note below);
 - (c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
 - (d) they present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: See Continuation Sheet.

3. Applicant's reply has overcome the following rejection(s): See Continuation Sheet.
4. Newly proposed or amended claim(s) ____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: ____.

Claim(s) objected to: ____.

Claim(s) rejected: 1-10.

Claim(s) withdrawn from consideration: ____.

8. The proposed drawing correction filed on ____ is a) approved or b) disapproved by the Examiner.

9. Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s). ____.

10. Other: See Continuation Sheet

Continuation of 2. NOTE:

New matter: In claims 1 and 4, the phrase "and a second wash at 45C in a solution comprising 0.1X SSC" is not supported by the specification. Example 8 only discusses the wash in 2X SSC at 45C. Sambrook et al provides no support for a second wash at 45C in a solution comprising 0.1X SSC.

Continuation of 3. Applicant's reply would have overcome the following rejection(s): the 102 rejections, because recitation of the hybridization conditions eliminates the cited references as prior art.

Continuation of 5. does NOT place the application in condition for allowance because:

112, 1st enablement: Applicant urges that the recitation of hybridization conditions and the teaching of assays for hypersensitive response elicitors enables the invention. Applicant also urges that cancellation of claims directed to transformed plants makes that aspect of the rejection moot. This is not found persuasive because the specification does not teach nucleic acids that hybridize under the recited conditions.

112, 1st written description: Applicant urges that one of ordinary skill in the art would realize that Applicant was in possess of nucleic acid that encode hrpW homologs. Applicant also urges that hypersensitive response elicitor proteins have a characteristic amino acid composition and properties. This is not found persuasive because the specification does not describe the structural features of nucleic acids that hybridize under the recited conditions.

Continuation of 10. Other:

The Kim reference cited in the 102 rejection prior Office actions is the one entitled "Hrp-secreted proteins and avirulence protein homolog"

Claims 2 and 3 would be allowable if made independent claims.

The amendments to the specification would be entered if presented with allowable claims.

DAVID T. FOX
PRIMARY EXAMINER
GROUP 180

1638
